| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, November 2007, p. 4181-4183, Vol. 51, No. 11
0066-4804/07/$08.00+0 doi:10.1128/AAC.00614-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

CHU Clermont-Ferrand, Centre de Biologie, Laboratoire de bactériologie clinique, Clermont-Ferrand F-63003, France,1 Univ. Clermont 1, UFR Médecine, Laboratoire de bactériologie, EA3844, Clermont-Ferrand F-63001, France,2 CHU Clermont-Ferrand, Hôtel-Dieu, Service de Réanimation Adulte, Clermont-Ferrand F-63003, France3
Received 10 May 2007/ Returned for modification 20 July 2007/ Accepted 10 August 2007
TEM-158 was found to include the substitutions previously observed for TEM-12 and TEM-35. This enzyme presented hydrolytic activity against ceftazidime and a high level of resistance against clavulanate, which can alter its detection. Its discovery highlights the need for accurate detection methods.
Published ahead of print on 20 August 2007.
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |